CN109311859A - 用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物 - Google Patents

用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物 Download PDF

Info

Publication number
CN109311859A
CN109311859A CN201780023642.5A CN201780023642A CN109311859A CN 109311859 A CN109311859 A CN 109311859A CN 201780023642 A CN201780023642 A CN 201780023642A CN 109311859 A CN109311859 A CN 109311859A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780023642.5A
Other languages
English (en)
Other versions
CN109311859B (zh
Inventor
施能扬
陈斌
张蕾
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Jiayue Pharmaceutical Technology Co., Ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109311859A publication Critical patent/CN109311859A/zh
Application granted granted Critical
Publication of CN109311859B publication Critical patent/CN109311859B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

公开了一类用于治疗纤维化相关疾病的化合物，具体公开了式(I)所示化合物和其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201780023642.5A 2016-04-14 2017-04-14 用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物 Active CN109311859B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610232306 2016-04-14
CN2016102323069 2016-04-14
PCT/CN2017/080599 WO2017177974A1 (zh) 2016-04-14 2017-04-14 用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物

Publications (2)

Publication Number Publication Date
CN109311859A true CN109311859A (zh) 2019-02-05
CN109311859B CN109311859B (zh) 2022-01-21

Family

ID=60042350

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780023642.5A Active CN109311859B (zh) 2016-04-14 2017-04-14 用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物

Country Status (9)

Country Link
US (1) US10604513B2 (zh)
EP (1) EP3444247B1 (zh)
JP (1) JP6923634B2 (zh)
CN (1) CN109311859B (zh)
AU (1) AU2017251555B2 (zh)
CA (1) CA3020779A1 (zh)
RU (1) RU2738844C2 (zh)
WO (1) WO2017177974A1 (zh)
ZA (1) ZA201807404B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364097A (zh) * 2021-05-20 2022-11-22 广州嘉越医药科技有限公司 一种含杂原子环丁烷取代基的吡啶酮衍生物的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7360171B2 (ja) * 2017-07-31 2023-10-12 ワシントン・ユニバーシティ Ｂリンパ球活性の調節及び臓器保護のためのピルフェニドン誘導体
US11198686B2 (en) * 2017-10-13 2021-12-14 Guangzhou Joyo Pharmatech Co., Ltd. Crystal form and salt form of pyridone compound and preparation method therefor
CN108727309B (zh) * 2018-06-20 2023-04-07 天津全和诚科技有限责任公司 一种3-氧杂环丁烷羧酸的合成方法
CN117045657A (zh) * 2022-05-12 2023-11-14 广州嘉越医药科技有限公司 一种药物组合及其应用
CN117398383A (zh) * 2022-07-14 2024-01-16 广州嘉越医药科技有限公司 一种吡啶酮衍生物的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284945A (zh) * 1997-12-19 2001-02-21 安姆根有限公司 取代的吡啶和哒嗪化合物及其药物用途
CN102099036A (zh) * 2008-06-03 2011-06-15 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
CN102786467A (zh) * 2012-08-15 2012-11-21 浙江省医学科学院 一种n-取代芳基吡啶酮化合物及其制备方法和应用
CN104822687A (zh) * 2012-10-02 2015-08-05 英特穆恩公司 抗纤维化吡啶酮类
WO2015153683A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2591784B1 (en) * 2005-05-10 2016-09-14 Intermune, Inc. Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system
CN102292124A (zh) * 2009-01-26 2011-12-21 英特芒尼公司 用于治疗急性心肌梗死和相关疾患的方法
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US20140094456A1 (en) * 2012-10-02 2014-04-03 Intermune, Inc. Anti-fibrotic pyridinones

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284945A (zh) * 1997-12-19 2001-02-21 安姆根有限公司 取代的吡啶和哒嗪化合物及其药物用途
CN102099036A (zh) * 2008-06-03 2011-06-15 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
CN102786467A (zh) * 2012-08-15 2012-11-21 浙江省医学科学院 一种n-取代芳基吡啶酮化合物及其制备方法和应用
CN104822687A (zh) * 2012-10-02 2015-08-05 英特穆恩公司 抗纤维化吡啶酮类
WO2015153683A1 (en) * 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364097A (zh) * 2021-05-20 2022-11-22 广州嘉越医药科技有限公司 一种含杂原子环丁烷取代基的吡啶酮衍生物的应用
WO2022242769A1 (zh) * 2021-05-20 2022-11-24 广州嘉越医药科技有限公司 一种含杂原子环丁烷取代基的吡啶酮衍生物的应用

Also Published As

Publication number Publication date
RU2738844C2 (ru) 2020-12-17
RU2018139801A (ru) 2020-05-14
AU2017251555B2 (en) 2021-04-29
RU2018139801A3 (zh) 2020-05-14
ZA201807404B (en) 2019-08-28
CN109311859B (zh) 2022-01-21
JP6923634B2 (ja) 2021-08-25
AU2017251555A1 (en) 2018-11-29
CA3020779A1 (en) 2017-10-19
EP3444247B1 (en) 2022-11-30
JP2019515950A (ja) 2019-06-13
EP3444247A4 (en) 2019-09-11
EP3444247A1 (en) 2019-02-20
US20190062315A1 (en) 2019-02-28
WO2017177974A1 (zh) 2017-10-19
US10604513B2 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
CN109311859A (zh) 用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物
CN105682656B (zh) 调节法尼醇x受体的组合物和方法
CN109071538A (zh) 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN109415406B (zh) 羊毛甾醇前药化合物及其制备方法和应用
CN109071564A (zh) 乙型肝炎病毒表面抗原抑制剂
CN104379583B (zh) 作为wnt信号传导抑制剂的化合物、组合物及其应用
CN107531711A (zh) Janus激酶抑制剂
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
TWI714566B (zh) 軸手性異構體及其製備方法和製藥用途
JP6724246B2 (ja) チオフェン化合物、その合成方法及び医療における応用
MXPA06011829A (es) Derivados de 1-amino-ftalazina, su preparacion, y su aplicacion terapeutica.
CN110092745B (zh) 一种含芳环的化合物及其应用
CN106470992B (zh) 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN106573934A (zh) 瞬时受体电位a1离子通道的抑制
CN109415341A (zh) 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
CN108884107B (zh) 乙型肝炎病毒表面抗原抑制剂
CN109661395A (zh) Pde4抑制剂
CN105085478B (zh) 异喹啉磺胺衍生物及其药物组合物和制药用途
CN110372723A (zh) 乙型肝炎病毒表面抗原抑制剂
AU2019217408B2 (en) Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
CN109563051A (zh) 作为pde4抑制剂的并环类化合物
CN110382463A (zh) Hdac6选择性抑制剂及其制备方法和应用
CN110023286A (zh) 作为ccr2/ccr5受体拮抗剂的联苯化合物
CN110418790B (zh) 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物
CN102946882A (zh) 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40000951

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200413

Address after: Room 526, building D, 39 Ruihe Road, Science City, Guangzhou hi tech Industrial Development Zone, Guangdong Province

Applicant after: Guangzhou Jiayue Pharmaceutical Technology Co., Ltd

Applicant after: MEDSHINE DISCOVERY Inc.

Address before: 050035 Innovation Building, 315 Changjiang Avenue, Shijiazhuang High-tech Zone, Hebei Province, 3rd Floor

Applicant before: MEDSHINE DISCOVERY Inc.

GR01 Patent grant
GR01 Patent grant